RegisterLogin

Linsitinib

CAT: 0804-HY-10191-01Size: 5 mgDry Ice: NoHazardous: No
CAT#: HY-10191-01Size: 5 mg
Selected
PRICE
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively[1].
CAS Number
[867160-71-2]
Product Name Alternative
OSI-906
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
IGF-1R; Insulin Receptor
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Linsitinib.html
Purity
99.87
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O[C@@]1(C)C[C@@H](C2=NC(C3=CC=C4C=CC(C5=CC=CC=C5)=NC4=C3)=C6C(N)=NC=CN62)C1
Molecular Formula
C26H23N5O
Molecular Weight
421.49
Precautions
H302, H315, H319, H335
References & Citations
[1]Mulvihill MJ, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and IR. Future Med Chem. 2009 Sep;1 (6) :1153-71.|[2]McKinley ET, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 2011 May 15;17 (10) :3332-40.|[3]Li W, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med. 2015 Apr 15;8 (4) :6563-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Related Products

CatalogName

Alternative Products

CatalogName
T6017-01Linsitinib
A8334-5Linsitinib
TRC-L469020-5MGLinsitinib
bs-83031C-01Linsitinib
202096Linsitinib
MBS3606298-01Linsitinib
sc-396762Linsitinib
M16302-01Linsitinib
015629-01Linsitinib
A8334-SLinsitinib

Popular Products